Bibliographic Details
| Title: |
Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study ( PROACTIVE). |
| Authors: |
Styles, Lori, Wager, Carrie G., Labotka, Richard J., Smith-Whitley, Kim, Thompson, Alexis A., Lane, Peter A., McMahon, Lillian E. C., Miller, Robin, Roseff, Susan D., Iyer, Rathi V., Hsu, Lewis L., Castro, Oswaldo L., Ataga, Kenneth I., Onyekwere, Onyinye, Okam, Maureen, Bellevue, Rita, Miller, Scott T. |
| Source: |
British Journal of Haematology; Jun2012, Vol. 157 Issue 5, p627-636, 10p, 2 Diagrams, 2 Charts, 1 Graph |
| Subject Terms: |
FEASIBILITY studies, SICKLE cell anemia, PHOSPHOLIPASES, BLOOD testing, HEALTH risk assessment, LEUKOCYTES |
| Abstract: |
Acute chest syndrome ( ACS) is defined as fever, respiratory symptoms and a new pulmonary infiltrate in an individual with sickle cell disease ( SCD). Nearly half of ACS episodes occur in SCD patients already hospitalized, potentially permitting pre-emptive therapy in high-risk patients. Simple transfusion of red blood cells may abort ACS if given to patients hospitalized for pain who develop fever and elevated levels of secretory phospholipase A2 ( sPLA2). In a feasibility study ( PROACTIVE; NCT00951808), patients hospitalized for pain who developed fever and elevated sPLA2 were eligible for randomization to transfusion or observation; all others were enrolled in an observational arm. Of 237 enrolled, only 10 were randomized; one of the four to receive transfusion had delayed treatment. Of 233 subjects receiving standard care, 22 developed ACS. A threshold level of sPLA2 ≥ 48 ng/ml gave optimal sensitivity (73%), specificity (71%) and accuracy (71%), but a positive predictive value of only 24%. The predictive value of sPLA2 was improved in adults and patients with chest or back pain, lower haemoglobin concentration and higher white blood cell counts, and in those receiving less than two-thirds maintenance fluids. The hurdles identified in PROACTIVE should facilitate design of a larger, definitive, phase 3 randomized controlled trial. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
